Candriam S.C.A. Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Candriam S.C.A. increased its holdings in Ultragenyx Pharmaceutical Inc. by 8.0%, purchasing an additional 53,760 shares, bringing its total ownership to approximately 0.77% valued at $26,361,000.
• A variety of institutional investors have also boosted their stakes in Ultragenyx, with Capital Fund Management S.A. and EntryPoint Capital LLC raising their holdings by 40.5% and 58.3%, respectively.
• Ultragenyx Pharmaceutical's stock recently experienced a 0.8% increase in value, with current trading at $29.36 and analysts projecting an average price target of $81.50.

Candriam S.C.A. raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.0% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 728,017 shares of the biopharmaceutical company's stock after purchasing an additional 53,760 shares during the period. Candriam S.C.A. owned approximately 0.77% of Ultragenyx Pharmaceutical worth $26,361,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Federated Hermes Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after buying an additional 5,400 shares in the last quarter. Deutsche Bank AG increased its position in shares of Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after acquiring an additional 8,385 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Ultragenyx Pharmaceutical by 100.0% during the fourth quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $63,105,000 after acquiring an additional 750,000 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in Ultragenyx Pharmaceutical by 23.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after acquiring an additional 269,733 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Ultragenyx Pharmaceutical by 81.0% in the fourth quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock worth $49,764,000 after purchasing an additional 529,217 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $0.18 during midday trading on Tuesday, hitting $29.09. 289,767 shares of the company traded hands, compared to its average volume of 1,290,517. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $60.37. The firm has a market cap of $2.80 billion, a P/E ratio of -5.26 and a beta of 0.25. The stock has a 50-day moving average of $31.54 and a 200-day moving average of $35.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the previous year, the company earned ($1.52) earnings per share. Ultragenyx Pharmaceutical's revenue for the quarter was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RARE. Cantor Fitzgerald decreased their target price on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective for the company in a report on Monday, July 28th. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Finally, Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.